Newspring Capital and Kineticos Life Sciences led a $22m round in Kincell Bio.

Newspring Capital, a private equity firm, and Kineticos Life Sciences, a growth equity and venture firm, led a $22m round in Kincell Bio, a scientifically focused, cell therapy development and manufacturing company. "We are excited to partner with the experienced team at NewSpring and to have them join our existing investors to support Kincell Bio, as we continue to scale our operations and deliver high-quality, flexible and scalable solutions to our partners in the cell therapy space," Mark R. Bamforth, Kincell Bio CEO.